

13 May 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: AstraZeneca's Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 May 2024, including: [AstraZeneca PLC's](#) Vaxzevria farewell; the next wave of cardiometabolics; [Pfizer Inc.](#) recruits prominent analyst: foundation pleas for China rare disease therapies; and [Gossamer Bio, Inc.](#) partners up for respiratory therapy.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up](#)" - Scrip, 8 May, 2024.)

(Also see "[Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies](#)" - Scrip, 8 May, 2024.)

(Also see "[Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy](#)" - Scrip, 6 May, 2024.)

(Also see "[*China's First Non-Profit Rare Disease Foundation Pleas For Therapies*](#)" - Scrip, 8 May, 2024.)

(Also see "[*Gossamer Partners With Chiesi To Accelerate Seralutinib Development*](#)" - Scrip, 6 May, 2024.)

[Click here to explore this interactive content online](#) ✨